Translational Research in Gastrointestinal Disorders [TARGID], Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium.
Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium; Jessa Hospital, Hasselt, Belgium.
J Crohns Colitis. 2018 Jan 24;12(2):178-187. doi: 10.1093/ecco-jcc/jjx122.
Endoplasmic reticulum [ER] stress was shown to be pivotal in the pathogenesis of inflammatory bowel disease. Despite progress in inflammatory bowel disease [IBD] drug development, not more than one-third of patients achieve steroid-free remission and mucosal healing with current therapies. Furthermore, patient stratification tools for therapy selection are lacking. We aimed to identify and quantify epithelial ER stress in a patient-specific manner in an attempt towards personalised therapy.
A biopsy-derived intestinal epithelial cell culture system was developed and characterised. ER stress was induced by thapsigargin and quantified with a BiP enzyme-linked immunosorbent assay [ELISA] of cell lysates from 35 patients with known genotypes, who were grouped based on the number of IBD-associated ER stress and autophagy risk alleles.
The epithelial character of the cells was confirmed by E-cadherin, ZO-1, and MUC2 staining and CK-18, CK-20, and LGR5 gene expression. Patients with three risk alleles had higher median epithelial BiP-induction [vs untreated] levels compared with patients with one or two risk alleles [p = 0.026 and 0.043, respectively]. When autophagy risk alleles were included and patients were stratified in genetic risk quartiles, patients in Q2, Q3, and Q4 had significantly higher ER stress [BiP] when compared with Q1 [p = 0.034, 0.040, and 0.034, respectively].
We developed and validated an ex vivo intestinal epithelial cell culture system and showed that patients with more ER stress and autophagy risk alleles have augmented epithelial ER stress responses. We thus presented a personalised approach whereby patient-specific defects can be identified, which in turn could help in selecting tailored therapies.
内质网(ER)应激被认为是炎症性肠病发病机制的关键。尽管在炎症性肠病(IBD)药物开发方面取得了进展,但目前的治疗方法中,只有不超过三分之一的患者能够实现无类固醇缓解和黏膜愈合。此外,缺乏用于治疗选择的患者分层工具。我们旨在以个体化的方式在患者中识别和量化上皮 ER 应激,以尝试进行个体化治疗。
开发并表征了一种基于活检的肠上皮细胞培养系统。通过使用 thapsigargin 诱导 ER 应激,并通过对 35 名已知基因型患者的细胞裂解物进行 BiP 酶联免疫吸附试验(ELISA)来定量 ER 应激,这些患者根据 IBD 相关 ER 应激和自噬风险等位基因的数量进行分组。
通过 E-钙黏蛋白、ZO-1 和 MUC2 染色以及 CK-18、CK-20 和 LGR5 基因表达证实了细胞的上皮特征。与具有一个或两个风险等位基因的患者相比,具有三个风险等位基因的患者的上皮 BiP 诱导(与未处理相比)水平更高[分别为 p = 0.026 和 0.043]。当包括自噬风险等位基因并根据遗传风险四分位将患者分层时,与 Q1 相比,Q2、Q3 和 Q4 中的患者的 ER 应激(BiP)明显更高[分别为 p = 0.034、0.040 和 0.034]。
我们开发并验证了一种体外肠上皮细胞培养系统,并表明具有更多 ER 应激和自噬风险等位基因的患者具有增强的上皮 ER 应激反应。因此,我们提出了一种个体化方法,通过该方法可以识别患者的特定缺陷,从而有助于选择量身定制的治疗方法。